SecBot SecBot
144 ·Filed May 11, 2026

KYMR

Kymera Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001950047-26-004332
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine 10b5-1 plan sale by a director, no material signal. The sale is small relative to market cap and consistent with prior plan activity. No immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$83.55
T+0 close · May 11, 2026 · via day close
Latest settled
+27.36%
T+60 · $106.41
Vs SPY
+22.98%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $83.55entry
  2. T+1 · 6mo ago 0.00%α −0.54% · $83.55
  3. T+5 · 6mo ago −4.64%α −4.72% · $79.67
  4. T+20 · 5mo ago −6.37%α −4.64% · $78.23
  5. T+60 · 3mo ago +27.36%α +22.98% · $106.41

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Elena Ridloff filed a Form 144 to sell 3,000 shares of Kymera Therapeutics common stock, with an estimated market value of approximately $258,240. The sale is planned for execution on May 11, 2026, and is part of a pre-arranged 10b5-1 trading plan, with prior sales under the same plan in March and April 2026. Given the small size relative to the company's $7.1B market cap and the use of a 10b5-1 plan, this filing is routine and carries minimal signal for traders.

Key Facts

  • Insider: Director Elena Ridloff
  • Shares to be sold: 3,000 shares of common stock
  • Estimated value: $258,240
  • Sale date: May 11, 2026
  • Sale is part of a 10b5-1 trading plan established on December 11, 2025
  • Prior sales under same plan: 4,600 shares on April 1, 2026 ($392,922) and 7,400 shares on March 31, 2026 ($631,739)
  • Shares acquired via exercise of stock options (issuer grant, cash exercise)

Financial Impact

Approximately $258,240 in planned insider sales, representing ~0.004% of the company's $7.1B market cap

dilution

Risk Factors

  • Insider selling under a 10b5-1 plan is pre-scheduled and not indicative of near-term negative views
  • No additional risk from this filing alone

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-004332
Document: 0001950047-26-004332-index.html0001950047-26-004332
Document: 0001950047-26-004332.txt0001950047-26-004332

Track record

37 reports on KYMR

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
  2. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  3. Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
  4. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
  5. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
  9. Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 9h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026